Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 8.5% – Time to Sell?

Posted by Donald Scott on Nov 13th, 2024

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) were down 8.5% during mid-day trading on Monday . The stock traded as low as $3.52 and last traded at $3.79. Approximately 26,219 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 25,676 shares. The stock had previously closed at $4.14.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH upped their target price on Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Check Out Our Latest Report on MRKR

Marker Therapeutics Price Performance

The firm’s fifty day moving average price is $3.27 and its 200-day moving average price is $3.93.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share (EPS) for the quarter. The company had revenue of $1.17 million for the quarter. Marker Therapeutics had a negative return on equity of 78.91% and a negative net margin of 278.27%. Sell-side analysts expect that Marker Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. increased its position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) by 52.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned about 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.